CORESTEMCHEMON Inc.

A166480

KR7166480004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
11,530 ^KRW	-1.37%		-2.45%	+70.31%

Mar. 26	CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	CI
Mar. 22	CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	CI

CORESTEMCHEMON Inc.(KOSDAQ:A166480) dropped from S&P Global BMI Index

August 24, 2023 at 12:00 am EDT

Latest news about CORESTEMCHEMON Inc.

CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	Mar. 25	CI
CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	Mar. 21	CI
CORESTEMCHEMON Inc.(KOSDAQ:A166480) dropped from S&P Global BMI Index	23-08-24	CI
CORESTEMCHEMON Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
CORESTEMCHEMON Inc. announced that it has received KRW 32.31145 billion in funding from a group of investors	23-01-25	CI
CORESTEMCHEMON Inc. announced that it expects to receive KRW 32.31145 billion in funding from a group of investors	23-01-16	CI
CORESTEMCHEMON Inc. announced that it has received KRW 10.81145 billion in funding	22-12-31	CI
CORESTEM Inc. completed the acquisition of the remaining 47% stake in ChemOn Inc..	22-11-30	CI
CORESTEM Inc. agree to acquire remaining 47% stake in ChemOn Inc. for KRW 90 billion	22-08-15	CI
CORESTEM Inc. announced that it has received KRW 41 billion in funding from a group of investors	20-06-25	CI
Corestem, Inc. announced that it expects to receive KRW 41 billion in funding from a group of investors	20-06-24	CI
Kadimastem Ltd. announced that it expects to receive $7 million in funding from Corestem, Inc.	16-12-06	CI
Corestem, Inc.(KOSDAQ:A166480) added to Russell Global Index	15-10-01	CI
Corestem, Inc.(KOSDAQ:A166480) added to S&P Global BMI Index	15-09-21	CI
Corestem, Inc. has completed an IPO in the amount of KRW 40.00 billion.	15-06-23	CI
Corestem Co., Ltd. has filed an IPO.	15-03-23	CI

Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CORESTEMCHEMON INC.	+70.31%	182M
IQVIA HOLDINGS INC.	+0.17%	42.86B
MODERNA, INC.	+10.92%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.23%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.63B
MEDPACE HOLDINGS, INC.	+26.69%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.92B
UNITED THERAPEUTICS CORPORATION	+6.57%	11.21B